As potential biomarkers, VEGFA and EGFR are very important for early diagnosis and clinical treatment of RA, because they can help predict the disease development of subjects at risk, provide prognostic information that can be used to make treatment choices and evaluate treatment response and results, and can monitor disease activity and progress. Here, EGFR is linked to rheumatoid arthritis.